Nuvation Bio Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by Nuvation Bio Inc. on May 21, 2025. The meeting addressed the election of directors, ratification of the independent auditor, and advisory approval of executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders representing 82.8% of Class A Common Stock and 100% of Class B Common Stock were present, constituting a quorum. The following proposals were approved:
- Proposal 1 (Election of Directors): Kathryn E. Falberg (Class A) and David Hung, M.D. (Class B) were elected to serve until the 2028 annual meeting.
- Proposal 2 (Ratification of Auditor): KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Proposal 3 (Executive Compensation): Stockholders approved, on an advisory basis, the compensation of the named executive officers.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.
Key Facts for Investor Verification
- Verify the full voting breakdown for the election of Kathryn E. Falberg, noting 64,812,107 broker non-votes.
- Confirm the ratification of KPMG LLP for the 2025 fiscal year.
- Review the definitive proxy statement filed on April 8, 2025, for detailed executive compensation data referenced in Proposal 3.
- Note that 1,000,000 shares of Class B Common Stock were voted entirely in favor of the Class B director election.